Hepatology home hospital program for people with advanced liver disease
Official title: HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease
Run by Massachusetts General Hospital · NCT05205954 · Data updated 2026-11-12
This will try a hospital-at-home program that brings hepatology care to adults with cirrhosis who would otherwise need inpatient care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 2 sites (Boston, Massachusetts and 1 other locations) |
| Status | Recruiting |
| Started | July 21, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | October 7, 2026 |
| Trial ID | NCT05205954 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with cirrhosis who present to the ED or inpatient medicine service and have ascites requiring diuretics or paracentesis, hepatic hydrothorax requiring diuretics, or hepatic encephalopathy requiring medications, with MELD ≤20 and who meet MGH Home Hospital criteria are ideal candidates.
✕Probably not a fit
Patients with prior solid-organ transplant, on hemodialysis, MELD >20, very low cognitive screening (S-ANT1 <10), current hemodynamically significant GI bleeding or alcohol withdrawal, those needing routine controlled substances, or judged unsuitable by clinicians are unlikely to benefit from this home-based program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot interventional program offers inpatient-level hepatology care delivered at home by the Massachusetts General Hospital Home Hospital team. Eligible adults with cirrhosis presenting to the emergency department or general medicine service who have ascites, hepatic hydrothorax, or hepatic encephalopathy may be enrolled. Patients with prior solid-organ transplant, on hemodialysis, MELD >20, low cognitive screening (S-ANT1 <10), active hemodynamically significant GI bleed or alcohol withdrawal, or needing routine controlled substances are excluded. The program aims to replace or shorten hospital stays by providing monitoring, treatments, and procedures in the home setting under hospital oversight.
Why it matters
Potential benefit: If successful, the program could let eligible patients receive hospital-level hepatology care at home, reducing hospital stays and improving comfort and convenience.
How similar studies have gone: Hospital-at-home models have shown positive results for general medical admissions and some chronic conditions, but there is limited published data specifically on home hospital care for advanced liver disease.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adult patients ≥ 18 years old with diagnosis of cirrhosis based on histology, radiology, and/or elastography presenting to the emergency department or inpatient general medicine service 2. Patients must have one of the following: 1. Ascites (requiring diuretics or serial large volume paracenteses) 2. Hepatic hydrothorax (requiring diuretics) 3. Hepatic encephalopathy (requiring medications) Exclusion Criteria: All existing MGB home hospital criteria apply, with the following taking precedent for this specific condition 1. History of solid organ transplantation 2. On hemodialysis 3. MELD score \> 20 4. Score \<10 on Simplified Animal Naming Test (S-ANT1) 5. Current admission for hemodynamically significant GI bleeding or alcohol withdrawal 6. Require routine administration of controlled substances 7. Those deemed ineligible based on the MGH Home Hospital, inpatient medicine or hepatology clinician evaluation
Where it's running
-
Massachusetts General Hospital
Boston, Massachusetts, United States Recruiting -
Massachusetts General Hospital
Boston, Massachusetts, United States Recruiting
Study contacts
- Study coordinator: Nneka Ufere, MD, MSCE
- Email: nufere@partners.org
- Phone: 617-643-3408
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Even protein distribution plus exercise for people awaiting liver transplant
This trial tests whether spreading daily protein evenly and combining it with a 12-week exercise program improves nutrition, muscle mass, and function in people waiting for a liver transplant compared with uneven protein timing or usual advice.
-
Frailty, Nutrition, and Recovery in People Waiting for a Liver Transplant
This project will test whether measures of frailty, muscle loss, nutrition, and psychological health can predict outcomes for adults (18–65) on the liver transplant waiting list in Turkey.
-
Exploring muscle composition's impact on liver transplant outcomes
This study is testing how muscle health affects the success of liver transplants in patients with severe liver disease.
-
Using spleen size to help detect gastroesophageal varices in compensated cirrhosis
This study tests whether ultrasound measurements of spleen size can help identify esophageal varices in adults with compensated cirrhosis, compared with the standard endoscopy test.
-
Endovascular treatment outcomes after portal hypertension–related GI bleeding in cirrhosis
This study tests how well endovascular procedures for portal hypertension–related GI bleeding work in adults with cirrhosis, and what factors predict outcomes.
-
EUS-guided coil and glue vs glue injection for bleeding gastric varices in cirrhosis
This trial tests whether using endoscopic ultrasound to guide coils plus glue works better than glue alone for stopping bleeding from gastric varices in adults with cirrhosis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.